However, by switching Th1/Th17 to Th2 type immune response, IL-33 can reduce the development of atherosclerosis [15], graft rejection and EAE [16, 17], which are mainly mediated by Th1 and Th17 response. This evidence concerns the gene IL33 and atherosclerosis.